NCT02778893

Conmana Combined With Thalidomide to Treat NSCLC

A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 67 (estimated)
• Sponsor: Henan Provincial People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Our study the NSCLC harbors EGFR-mutation with Conmana combined with thalidomide as first-line treatment, is expected to improve further EGFR-Tyrosine kinase inhibitors (TKI) response rate (ORR), prolong time to progression (PFS), improve patient survival.

Detailed description

Primary Objective: To evaluate the efficacy, survival and side effects of the combined therapy, and to evaluate the effectiveness and safety of thalidomide with Conmana in patients who harbors EGFR mutations.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	Conmana	125mg three times a day (TID) continuously
DRUG	Thalidomide	100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-03-01
• Completion: 2020-03-01
• First posted: 2016-05-20
• Last updated: 2016-05-20

Locations

1 site across 1 country: China